Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 Operating Margin % is 43.11% as of Mar. 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Bio Essence ranks better than 99.58% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Bio Essence's Operating Income for the
three
months ended in Mar. 2026 was $0.22 Mil. Bio Essence's Revenue for the
three
months ended in Mar. 2026 was $0.50 Mil. Therefore, Bio Essence's Operating Margin % for the quarter that ended in Mar. 2026 was 43.11%.
The historical rank and industry rank for Bio Essence's Operating Margin % or its related term are showing as below:
BIOE'
s Operating Margin % Range Over the Past 10 Years
Min: -189.83 Med: -91.13 Max: 55.6
Current: 55.6
BIOE's Operating Margin % is ranked better than 99.58% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.57
vs BIOE: 55.60
Bio Essence's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Bio Essence's Operating Income for the
three
months ended in Mar. 2026 was $0.22 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $1.32 Mil.
Bio Essence (OTCPK:BIOE) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Bio Essence Operating Margin % Related Terms
Bio Essence Operating Margin % Historical Data
* Premium members only.
The historical data trend for Bio Essence's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOE vs BFRI, APUS, CABR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Bio Essence's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Bio Essence's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a Operating Margin % of 43.11% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #4 out of 961 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Bio Essence's Operating Margin % too high?
Bio Essence's current Operating Margin % is 43.11%. The Drug Manufacturers industry median Operating Margin % is 7.57. Bio Essence's value of 43.11% is 469.5% above this industry median. Based on the distribution chart, Bio Essence ranks #4 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Operating Margin % compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #4 out of 961 companies for Operating Margin %. This places Bio Essence in the top 0% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.57. Bio Essence's value of 43.11% is 469.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.57, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current Operating Margin % of 43.11% is 469.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current Operating Margin % is 43.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Operating Margin % of 43.11%. The current Operating Margin % is 43.11% and 469.5% above the Drug Manufacturers industry median of 7.57. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Bio Essence (BIOE), the current Operating Margin % is 43.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
